Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 2/20 | 0.47 |
| ▸ | GABRD | O14764 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.47 |
| ▸ | GABRE | P78334 | 2/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159977 | 0.85 | KIF11 (0.50) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL11141346 | 0.84 | KIF11 (0.57) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL9935634 | 0.82 | KIF11 (0.55) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL6048891 | 0.82 | KIF11 (0.47) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| Formaldehyde SCHEMBL491350 | 0.81 | KIF11 (0.59) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL28555232 | 0.81 | KIF11 (0.46) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL157116 | 0.81 | KIF11 (0.58) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL11577428 | 0.81 | KIF11 (0.53) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL21808458 | 0.81 | KIF11 (0.53) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL1735965 | 0.81 | KIF11 (0.53) | KIF11ALDH1A1HSD17B10GPR3GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114316137-A | High refractive index materials | 罗门哈斯电子材料有限责任公司 | 2022-04-12 | — | — | CN | claimed |
| EP-2630151-B1 | USE OF CYCLIC AZABORONATES AS SENSITIVE MATERIALS IN SENSORS INTENDED TO DETECT THE PRESENCE OF PEROXIDES IN A GASEOUS ENVIRONMENT | COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-04-12 | — | — | EP | claimed |
| CN-106045894-A | 3(4)-Substituted alkoxyphenoxy hydrocarbon PPAR (peroxisome proliferator-activated receptor) agonist and application thereof | 天津医科大学 | 2016-10-26 | — | — | CN | claimed |
| US-9194853-B2 | Use of cyclic azaboronates as sensitive materials in sensors for detecting the presence of peroxides in a gaseous environment | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-11-24 | — | — | US | claimed |
| US-20130260471-A1 | USE OF CYCLIC AZABORONATES AS SENSITIVE MATERIALS IN SENSORS FOR DETECTING THE PRESENCE OF PEROXIDES IN A GASEOUS ENVIRONMENT | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2013-10-03 | — | — | US | claimed |
| EP-1482931-B1 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA INC (US) | 2011-10-19 | — | — | EP | claimed |
| US-20090035302-A1 | Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith | TRANSTECH PHARMA, INC. (US) | 2009-02-05 | — | — | US | claimed |
| CN-1633290-A | Mono-and bicyclic pyrrole derivatives inhibiting ligand interaction with higher glycation end product receptors | TRANSTECH PHARMA INC (US) | 2005-06-29 | — | — | CN | claimed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | claimed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | claimed |
| CN-118244582-A | Negative photosensitive resin composition and cured film thereof | 罗门哈斯电子材料韩国有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-114316137-A | High refractive index materials | 罗门哈斯电子材料有限责任公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114245882-A | Photosensitive resin composition, method for producing patterned cured film, interlayer insulating film, covercoat, surface protective film, and electronic component | 艾曲迪微系统股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3929228-A1 | BATTERY MATERIAL AND ELECTRODE MATERIAL | Nissan Chemical Corporation (JP) | 2021-12-29 | — | — | EP | disclosed |
| US-20040127708-A1 | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | disclosed |
| EP-1375486-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035302-A1 | Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith | AGER, APP, BACE1 | KIF11 4876/4885ALDH1A1 3354/4885HSD17B10 4230/4885 |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | KIF11 4690/4885ALDH1A1 3202/4885HSD17B10 4008/4885 |
| US-20040127708-A1 | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity | DUT, PNP, INMT | KIF11 4227/4885ALDH1A1 1123/4885HSD17B10 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.